Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
199800.KQ
STRONG SELLToolGen Incorporated · Healthcare · South Korea · $266M · Avg Vol: $2M/d
11
StockRankQ
33
V
34
M
28
P/E (TTM)
—
ROE
-68.6%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
ToolGen Incorporated, a biotechnology company, focuses on the development of genome editing technology in South Korea. The company develops clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors for gene editing in eukaryotic cells.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 489,391 | 726,329 | 586,483 | 859,979 | 20.7% |
| EPS | -1.52 | -3.52 | 0.51 | -2.79 | — |
| Shares | 8M | 8M | 9M | 9M | +13.7% |
| Debt | 13,152 | 40M | 9M | 1M | 343.8% |
| Equity | 46M | 20M | 38M | 37M | -7.5% |
| Op CF | -10M | -10M | -11M | -13M | — |
| Inv CF | 12M | -471,454 | -2M | 8M | — |
| Fin CF | 584,212 | 22M | 533,777 | 650,748 | — |
Loading...
PRICE (1M)-54.5%
SMA 50SMA 200
Close
$30.28
RSI (14)
32.5
52W High
$93.47
From 52W High
0.3%
SCORE BREAKDOWN
Quality
33
ROIC
-62.1%10.3
ROE
-68.6%12.4
GP/Assets
2.2%14.4
Op. Margin
-1175.6%6.6
FCF/Assets
-22.9%14.3
Piotroski
—28.7
Int. Cover
-32.9x15.8
D/E Ratio
0.00x94.4
Current Ratio
10.94x88.4
Value
34
P/E (TTM)
—N/A
EV/EBITDA
-19.2x86.8
P/FCF
—N/A
P/B
7.0x16.7
P/S
257.6x4.8
Div Yield
—N/A
Momentum
28
52W High %
32%7.1
RS 6M
-130%6.5
SMA 50/200
1.30x94.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$266M
P/E (Forward)
—
Gross Margin
87.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 199800.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 199800.KQ | ToolGen Incorporated(you) | $266M | 11 | STRONG SELL |
| 304360.KQ | S.Biomedics Co., Ltd. | $225M | 9 | STRONG SELL |
| 215600.KQ | SillaJen, Inc. | $233M | 13 | STRONG SELL |
| 228760.KQ | Genomictree Inc. | $216M | 9 | STRONG SELL |
| 389650.KQ | NEXTBIOMEDICAL | $217M | 12 | STRONG SELL |
| 493280.KQ | IMBiologics | $259M | 2 | STRONG SELL |
| 468530.KQ | PROTEINA | $261M | 1 | STRONG SELL |
| 424870.KQ | ImmuneOncia | $252M | 1 | STRONG SELL |
| 372320.KQ | Curocell | $285M | 1 | STRONG SELL |
| 287840.KQ | IntoCell, Inc. | $227M | 2 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.4%